Madrigal Pharmaceuticals (MDGL) Invested Capital (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Invested Capital data on file, last reported at $883.8 million in Q1 2026.

• Invested Capital for Q1 2026 came in at $883.8 million, up 6.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $883.8 million (up 6.65% YoY), and the FY2025 annual result was $942.6 million, up 8.1% from the prior year.
• Invested Capital eased to $883.8 million in Q1 2026 per MDGL's latest filing, from $942.6 million in the prior quarter.
• Over five years, Invested Capital peaked at $973.7 million in Q2 2024 and troughed at $78.5 million in Q3 2022.
• A 5-year average of $586.7 million and a median of $814.4 million in 2025 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2022 and 2024: Invested Capital sank 66.57% in 2022, then surged 422.52% in 2024.
• A 5-year view of Invested Capital shows it stood at $267.1 million in 2022, then jumped by 95.01% to $520.8 million in 2023, then soared by 67.42% to $872.0 million in 2024, then grew by 8.1% to $942.6 million in 2025, then dropped by 6.24% to $883.8 million in 2026.
• Business Quant data shows MDGL's Invested Capital at $883.8 million in Q1 2026, $942.6 million in Q4 2025, and $965.5 million in Q3 2025.